Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 221 to 230 of 2451 total matches.
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction
Suflave — A Low-Volume Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
regimens are hyperosmotic and require consumption
of 2-3 liters of fluid.1
MECHANISM OF ACTION — Suflave ...
The FDA has approved Suflave (Sebela/Braintree), a
low-volume polyethylene glycol (PEG)- and sulfate-based
product for cleansing of the colon prior to
colonoscopy in adults. Other oral colonoscopy
preparations available in the US are listed in
Table 2. Suflave is marketed as tasting better than
other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51 doi:10.58347/tml.2023.1685b | Show Introduction Hide Introduction
Tafluprost (Zioptan) - A New Topical Prostaglandin for Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 16, 2012 (Issue 1388)
, but prostaglandin analogs are
probably the most widely used.1 By increasing
uveoscleral outflow, they lower ...
The FDA has approved tafluprost ophthalmic solution
(Zioptan – Merck), a prostaglandin analog, for reduction
of intraocular pressure in patients with open-angle glaucoma
or ocular hypertension. It is being marketed as the
first preservative-free topical prostaglandin
Setmelanotide (Imcivree) for Rare Genetic Forms of Obesity (online only)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
subtilisin/kexin type 1 (PCSK1) deficiency, or leptin
receptor (LEPR) deficiency. for age (6 to ...
The FDA has approved setmelanotide (Imcivree –
Rhythm), a subcutaneously injected melanocortin 4
(MC4) receptor agonist, for chronic weight management
in patients ≥6 years old with obesity due to
pro-opiomelanocortin (POMC) deficiency, proprotein
subtilisin/kexin type 1 (PCSK1) deficiency, or leptin
receptor (LEPR) deficiency.
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
obstructive pulmonary disease
1. Adult and pediatric patients (≥12 years old and weighing ≥40 kg) with ≥1 ...
In February 2021, the FDA issued an Emergency Use
Authorization (EUA) for the investigational monoclonal
antibodies bamlanivimab and etesevimab (Lilly) for
use together to treat mild to moderate COVID-19
in persons ≥12 years old who weigh ≥40 kg and
are at high risk of progression to severe disease or
hospitalization. The FDA has now expanded this
EUA to allow use of the antibodies together for post-exposure
prophylaxis of COVID-19 in such persons
if they are not fully vaccinated against COVID-19 or
are unlikely to have an adequate immune response
to full vaccination and have...
Biktarvy - Another INSTI-Based Combination for HIV
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018 (Issue 1553)
), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who ...
The FDA has approved Biktarvy (Gilead), a once-daily,
fixed-dose combination of bictegravir, a new integrase
strand transfer inhibitor (INSTI), and the nucleoside
reverse transcriptase inhibitors (NRTIs) emtricitabine
and tenofovir alafenamide (TAF), for treatment of HIV-1
infection in adults. The new combination is indicated for
use in patients who are antiretroviral-naive or who have
been virologically suppressed on a stable antiretroviral
regimen for ≥3 months with no history of treatment
failure and no known substitutions associated with
resistance to any component of the...
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
, and Y (MenACWY; Menveo, MenQuadfi)1 and
two meningococcal serogroup B vaccines (MenB;
Bexsero ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
Ambrisentan (Letairis) and Tadalafil (Adcirca) for Pulmonary Arterial Hypertension
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
phosphodiesterase-5 (PDE5) inhibitors, endothelin
receptor antagonists, and a guanylate cyclase
stimulator.1 ...
The FDA has approved the use of ambrisentan
(Letairis) and tadalafil (Adcirca) together for treatment
of pulmonary arterial hypertension (PAH). It is the first
2-drug regimen to be approved for this indication.
Voretigene Neparvovec-rzyl (Luxturna) for Inherited Retinal Dystrophy
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
in young adulthood.1
No effective treatments have been available. The
Argus II Retinal Prosthesis System ...
The FDA has approved voretigene neparvovec-rzyl
intraocular suspension (Luxturna – Spark), an
adeno-associated virus vector-based gene therapy,
for treatment of confirmed biallelic RPE65 mutation-associated
retinal dystrophy in patients who have viable
retinal cells. It is the first gene replacement therapy
approved in the US that targets a disease caused by
mutations in a specific gene and the first pharmacologic
treatment to be approved for this disorder.
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
polystyrene sulfonate and
patiromer (Veltassa)1 were approved earlier.
Pronunciation Key
Lokelma: low kel ...
The FDA has approved sodium zirconium cyclosilicate
(Lokelma – AstraZeneca), an oral potassium binder that
exchanges hydrogen and sodium for potassium in the
gastrointestinal (GI) lumen, for treatment of non-life-threatening
hyperkalemia in adults. Sodium zirconium
cyclosilicate (SZC) is the third drug to be approved
for this indication; sodium polystyrene sulfonate and
patiromer (Veltassa) were approved earlier.